Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.08.24 | Motus GI Holdings, Inc. - 15-12G, Securities registration termination | 5 | SEC Filings | ||
21.05.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.05.2024 | 2.590 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 21.05.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.05.2024.ISIN NameCA00379L1067 ABRASILV.... ► Artikel lesen | |
18.03.24 | Motus GI Holdings, Inc.: Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 248 | GlobeNewswire (Europe) | Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process... ► Artikel lesen | |
MOTUS GI Aktie jetzt für 0€ handeln | |||||
21.02.24 | Motus GI Holdings, Inc.: Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu System to Avoid Clogging in Cleansing the GI Tract | 244 | GlobeNewswire (Europe) | FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. ("the "Company") (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MEDTRONIC | 88,81 | +1,15 % | Manning & Napier Advisors LLC Has $23.10 Million Stake in Medtronic plc (NYSE:MDT) | ||
INTUITIVE SURGICAL | 559,40 | +1,73 % | Vor den Zahlen: Analysten optimistisch für Intuitive Surgical | © Foto: Sundry Photography - stock.adobe.comRoboter, die bei Operationen assisitieren: darauf ist das US-amerikanische Unternehmen Intuitive Surgical spezialisiert. Nach Börsenschluss gibt das Unternehmen... ► Artikel lesen | |
ROKU | 81,68 | +2,91 % | Roku (NASDAQ:ROKU) Trading Up 0% - Here's What Happened | ||
ATOSSA THERAPEUTICS | 0,827 | +0,73 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 | SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices | BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
CYTOSORBENTS | 1,032 | +6,83 % | CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue | Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor... ► Artikel lesen | |
QUIDELORTHO | 44,200 | +5,24 % | Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now | ||
VERU | 0,549 | -6,40 % | Veru Inc.: Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction | -- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 0,895 | +3,23 % | Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) | BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
CENTENE | 62,42 | +1,68 % | Can Centene's Q4 Earnings Navigate Through Rising Medical Costs? | ||
ONTRAK | 1,740 | 0,00 % | Ontrak Health Announces 2024 Third Quarter Financial Results | MIAMI--(BUSINESS WIRE)--Ontrak, Inc. (NASDAQ: OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results... ► Artikel lesen | |
NANO-X IMAGING | 7,510 | +0,20 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
SENSEONICS | 1,001 | 0,00 % | Senseonics (NYSE:SENS) Reaches New 12-Month High - Time to Buy? | ||
PATTERSON COMPANIES | 29,000 | -2,68 % | Patterson Companies Announces Expiration of "Go-Shop" Period | ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies, Inc. (Nasdaq: PDCO), a leading dental and animal health distributor, today announced the expiration of the 40-day "go-shop" period under the... ► Artikel lesen |